Sudarshan Pharma Industries has received approval to acquire 300 shares of face value of AED 1000 each of Cibachem General Trading L.L,C., Dubai, United Arab Emirates (Cibachem) equivalent to 100% of the paid up share capital of Clbachem at a consideration of Rs 25 lakh or its equivalent foreign exchange in UAE Dirhams (AED).
Upon completion of the acquisition, Cibachem would become a wholly-owned subsidiary of the Company. The acquisition of Cibachem will enable the Company to enlarge its customer base in the Middle East Region. The said acquisition is expected to be completed by March 31, 2025. The Board of Directors of the company at their meeting held on January 15, 2025 has approved the same.
Sudarshan Pharma Industries is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: